A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis
Phase 3
- Conditions
- Rheumatoid Arthritis
- Registration Number
- JPRN-jRCT2080222355
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- other
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Male or female patients at least 18 years of age who have been diagnosed with RA and have completed the final study visit in a previous baricitinib RA study
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method